Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation

August 21, 2019 Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma

AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …
News
teva_copy

Teva launch generic version of EpiPen for children

August 21, 2019 Research and Development Mylan, Teva, allergies, children, epipen, pharma

A generic version of Mylan’s EpiPen, manufactured by Teva, is now available for children weighing between 15kg and 30kg in …
News
astrazeneca_building_white

AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer

August 21, 2019 Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …
News
blood-1813410_960_720

NHS England to fund Hemlibra for patients with severe haemophilia

August 21, 2019 Research and Development Chugai, Hemlibra, Roche, haemophilia, pharma

NHS England is to fund Roche and Chugai Pharma UK’s haemophilia drug Hemlibra, for people with sever congenital haemophilia A …
News

Novartis exec pushed out over Zolgensma data scandal denies wrongdoing

August 21, 2019 Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma

Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …
News
733px-reduction_gear

Finding the needle in the haystack of rare disease

August 19, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Genomenon, Rare Genomics Institute, pharma, rare disease

Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory …
Feature
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …
News
regeneron

Regeneron therapy halves LDL cholesterol levels in rare genetic condition

August 15, 2019 Research and Development Regeneron, evinacumab, pharma, rare disease

Regeneron has reported a strong showing for its investigational angiopoietin-like 3 (ANGPTL3) antibody evinacumab in the treatment of the rare …
News
lilly_building_with_american_flag_web

Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis

August 15, 2019 Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …
News

FDA approve new drug for treatment-resistant TB

August 15, 2019 Research and Development FDA, TB, US, pharma, pretomanid, tuberculosis

The US FDA has approved BPaL, the TB Alliance’s treatment for drug-resistant tuberculosis (TB). The US regulator gave the go-ahead …
News
lynparza

Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations

August 14, 2019 Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …
News
janssen_latest_logo_on_sign_closer

Janssen chalks up two more indications in Europe for Imbruvica combo therapies

August 14, 2019 Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma

Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …
News

Aspen Pharmacare to pay £8 million after colluding to rip off NHS

August 14, 2019 Research and Development Addison's disease, Aspen Pharmacare, CMA, NHS, pharma

South African firm Aspen Pharmacare has agreed to pay £8 million to Britain’s NHS over a dispute about overpayment. The …
News
17096650341_abceee54b5_z

Living in polluted city for ten years increases risk of lung disease as much as pack of cigarettes a day for 29 years

August 14, 2019 Research and Development Air pollution, COPD, lung disease, pharma emphysema, public health

Air pollution in cities dramatically increases the risk for and risk of progression of emphysema, a form of chronic obstructive …
News
25482028522_7a08ece5bb_z1

Senate Finance Comittee Chairman, Chuck Grassley calls on Novartis to reveal details of data scandal

August 13, 2019 Research and Development AveXis, Chuck Grassley, Novartis, Zolgensma, sfc

Chuck Grassley, Chairman of the Senate Finance Committee, has demanded that Novartis give up details on the faulty data scandal …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026